• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Association between pre-existing Pulmonary Hypertension and COVID-19 related outcomes in inpatient and ambulatory care settings

tetano

Editor, Senior Moderator
PLoS One


. 2025 Apr 24;20(4):e0321964.
doi: 10.1371/journal.pone.0321964. eCollection 2025. Association between pre-existing Pulmonary Hypertension and COVID-19 related outcomes in inpatient and ambulatory care settings

Shilpa Vijayakumar[SUP] 1 [/SUP], David W Louis[SUP] 2 [/SUP], Emily Corneau[SUP] 3 [/SUP], Sebhat Erqou[SUP] 3 4 5 [/SUP], Stephen W Waldo[SUP] 6 7 8 [/SUP], Mary E Plomondon[SUP] 6 [/SUP], Madhura Gokhale[SUP] 6 [/SUP], Wasiq Sheikh[SUP] 3 4 5 [/SUP], Phinnara Has[SUP] 9 [/SUP], Saad Marwan[SUP] 4 5 [/SUP], J Dawn Abbott[SUP] 4 5 [/SUP], Matthew Jankowich[SUP] 3 10 [/SUP], Herbert D Aronow[SUP] 11 12 [/SUP], Wen-Chih Wu[SUP] 3 4 5 [/SUP], Gaurav Choudhary[SUP] 3 4 5 [/SUP]



Affiliations
Abstract

Background: Afflicting up to 1% of population, pulmonary hypertension (PH) is commonly associated with cardiopulmonary and metabolic diseases, but the effect of COVID-19 in patients with pre-existing PH remains unclear.
Methods: We conducted a retrospective cohort study in patients who had undergone right-heart-catheterization within the VA Healthcare system and had a subsequent hospital admission with COVID-19 (inpatient cohort, n=1204) or had COVID-19 positivity but not admitted (outpatient cohort, n=6576). Inpatient findings were confirmed in a non-VA validation cohort (n=656) who had undergone echocardiography with subsequent admission. PH was defined invasively as mean pulmonary artery pressure (mPAP) >20 mmHg and non-invasively as estimated right ventricular systolic pressure (RVSP) >30 mmHg. In-hospital outcomes (inpatient cohort) and 1-year mortality (outpatient cohort) were assessed using multivariable logistic or Cox regression adjusting for confounders.
Results: Pre-existing PH was independently associated with greater in-hospital mortality (PH using mPAP: adjusted odds ratio [aOR] 1.60, 95%CI: 1.04-2.46; PH using RVSP: aOR 2.12, 95% CI 1.18-3.82). Among outpatients, those with COVID-19 had >8-fold higher 90-day and 2.8 fold higher 91-365 day adjusted hazard of mortality irrespective of PH status. Hazards of 90-day hospitalization were similarly driven by COVID-19. The findings were comparable for patient subgroup with normal pulmonary capillary wedge pressures.
Conclusion: Pre-existing PH is independently associated with higher in-hospital COVID-19 mortality. In outpatients, COVID-19 positivity was associated with increased mortality over 1 year irrespective of PH status, with highest risk within the first 90 days.


 
Back
Top Bottom